Michael Rothenberg‘s Moab Capital Partners has filed a 13D with the SEC related to its long position in Perceptron, Inc. (NASDAQ:PRCP), in which it owned 210,804 shares at the end of 2015. The updated filing shows that Moab Capital now owns 617,870 shares, amounting to 6.6% of the company’s common stock.
Item 4 of the filing also reveals the following information:
“The Reporting Persons have recently expressed their concerns privately to the Board of Directors of the Issuer (the “Board”) regarding the Issuer’s underperformance as well as the opportunities that they believe are available to increase value for the benefit of all stockholders, including a reconstituted Board, and the Reporting Persons’ desire to work constructively with the Issuer to implement the changes that the Reporting Persons believe are necessary to drive stockholder value.”
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
(Amendment No. )1
(Name of Issuer)
Common Stock, $0.01 par value
(Title of Class of Securities)
CHAD H. GOLDSTEIN
MOAB CAPITAL PARTNERS, LLC
15 East 62nd Street
New York, New York 10065
ANDREW FREEDMAN, ESQ.
MEAGAN REDA, ESQ.
OLSHAN FROME WOLOSKY LLP
Park Avenue Tower
65 East 55th Street
New York, New York 10022
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
February 24, 2016
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.
1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now
The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)